EVTD Stock Overview
Operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Evotec SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €8.39 |
| 52 Week High | €9.59 |
| 52 Week Low | €5.20 |
| Beta | 1.11 |
| 1 Month Change | 34.93% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -67.66% |
| 5 Year Change | -65.34% |
| Change since IPO | 224.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| EVTD | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | 34.9% | -1.1% | -0.8% |
| 1Y | n/a | -13.6% | 4.0% |
Return vs Industry: Insufficient data to determine how EVTD performed against the UK Life Sciences industry.
Return vs Market: Insufficient data to determine how EVTD performed against the UK Market.
Price Volatility
| EVTD volatility | |
|---|---|
| EVTD Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 7.9% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in GB Market | 11.2% |
| 10% least volatile stocks in GB Market | 3.3% |
Stable Share Price: EVTD's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine EVTD's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 4,766 | Christian Wojczewski | www.evotec.com |
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. It operates in two segments, Shared R&D and Just Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, fibrosis, immunology, pain and inflammation, infectious, kidney, liver, rare, respiratory, fibrotic and metabolic disease; central nervous system (CNS) and cardio metabolic disorders; and animal and women health.
Evotec SE Fundamentals Summary
| EVTD fundamental statistics | |
|---|---|
| Market cap | €1.25b |
| Earnings (TTM) | -€206.98m |
| Revenue (TTM) | €788.22m |
Is EVTD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EVTD income statement (TTM) | |
|---|---|
| Revenue | €788.22m |
| Cost of Revenue | €680.87m |
| Gross Profit | €107.35m |
| Other Expenses | €314.33m |
| Earnings | -€206.98m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Aug 13, 2025
| Earnings per share (EPS) | -1.17 |
| Gross Margin | 13.62% |
| Net Profit Margin | -26.26% |
| Debt/Equity Ratio | 52.5% |
How did EVTD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/29 06:14 |
| End of Day Share Price | 2025/05/26 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Evotec SE is covered by 29 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Patrick Trucchio | Berenberg |
| Michael Ryskin | BofA Global Research |
| Alexandru Cogut | Bryan Garnier & Co |